KRAS and non-small cell lung carcinoma: As a result of its preference for C-Raf effector binding, KRAS Q61H NSCLC samples exhibited a greater level of ERK activity, compared to KRAS WT or G12D in the same cohort of NSCLC patient samples (Zhou et al., 2020).